Brendan Wood International

Closed

Photos

11 E 44th St
New York, NY 10017

Wakefield Talabisco International (WTI), founded in 1992, is a pioneering female minority-owned retained executive search firm based in New York City. The firm specializes in placing senior leaders and C-suite executives across various regions, including the United States, Europe, Latin America, Asia Pacific, and EMEA, while focusing on empowering innovation for future generations.

Led by Barbara Talabisco, WTI is committed to supporting the growth of multinational mid-size businesses and start-ups by providing top-tier executive talent. The firm's areas of expertise encompass sectors such as financial services, luxury retail, consumer goods, and healthcare, among others.

Generated from the website

Own this business?
See a problem?

You might also like

Jack Kelly & Partners LLC
Real estate managers, Art gallery, Investment advisory service

Jack Kelly & Partners LLC

New Leaf Venture Partners' objectives with each investment are to back a strong, entrepreneurial management team, to provide appropriate financial resources, to help build a great company, and to create exceptional equity value. We are active investors and almost always serve as directors of our portfolio companies, who can draw upon perspectives and experiences of the entire NLV investment team and its network of successful scientists, clinicians, operating executives and entrepreneurs. We assist in building management teams, guiding corporate strategy, providing input to operating plans, and in making decisions about optimal paths for future financings and exits. As conditions evolve, NLV Partners team continually refines its differentiated strategy in healthcare investing. Both of NLV's latest funds, New Leaf Ventures I and New Leaf Ventures II, focus on taking leadership positions in: Biopharmaceuticals - NLV has an in-depth understanding of therapeutic targets and modalities, the drug R&D process, clinical trial design, regulatory requirements, and pharmaceutical commercial activities. NLV's extensive medical, clinical development, commercial and financial experience helps companies navigate the challenging path to regulatory approval and commercialization as stand-alone companies or through value-added strategic partnerships. NLV invests in companies at all stages in this sector, but looks at the level of risk, costs, and timelines to build real value in the underlying program (s) in determining if an investment fits our strategy. NLV has been particularly active in starting and investing in companies that been formed around the spin out of programs from larger pharmaceutical and biotech companies. Medical devices - NLV works closely with its network of entrepreneurs and scientific and medical founders to identify investment opportunities around promising technologies targeting areas of high unmet medical need and large commercial potential. The current strategy is to focus on later stage opportunities to provide growth capital or the last round to profitability in which regulatory and reimbursement risks are minimal. NLV will invest in early stage companies when there are large established global markets and an opportunity to prove safety and effectiveness in a focused, cost effective program. NLV's investment team brings critical operating experience and the ability to evaluate the biological, engineering, regulatory, reimbursement and market risks most relevant to starting, growing, developing and exiting young or more mature companies in the medical devices sector.
United StatesNew YorkNew YorkBrendan Wood International

Partial Data by Infogroup (c) 2025. All rights reserved.

Partial Data by Foursquare.